Seasonix60 ml

Seasonix is a second-generation (low-sedating) antihistamine indicated for the following conditions:

Established / FDA-approved uses

• Seasonal allergic rhinitis — relief of nasal and non-nasal symptoms (sneezing, rhinorrhea, itching, ocular itching/tearing/redness) in adults and children.
• Perennial allergic rhinitis — relief of symptoms in adults and children (appropriate age depends on dosage form; oral solution is approved from 6 months of age, tablets from 6 years of age).
• Chronic idiopathic urticaria — treatment of uncomplicated skin manifestations (hives/itching) in patients 6 months of age and older, using the appropriate dosage form.

Seasonix is generally used as monotherapy for these allergic conditions and does not require combination with another agent to be effective for its labeled indications.

Each tablet/capsule typically contains Levocetirizine Dihydrochloride 5 mg as the active ingredient, along with pharmaceutically acceptable excipients such as microcrystalline cellulose, lactose, colloidal silicon dioxide, and magnesium stearate. Oral solution formulations contain Levocetirizine Dihydrochloride 2.5 mg/5 mL. Exact excipients vary by manufacturer; refer to the specific product label for full composition details.

Seasonix is the active R-enantiomer of the racemic antihistamine cetirizine. It is a second-generation, selective histamine H1-receptor antagonist belonging to the piperazine derivative class of antihistamines. Compared with first-generation antihistamines, it has a substantially lower propensity to cross the blood-brain barrier and cause sedation, although mild somnolence can still occur in some patients (it is not classified as a truly "non-sedating" agent). It is used orally, once daily, for the symptomatic relief of allergic conditions.

Seasonix belongs to the class of second-generation (low-sedating) H1-antihistamines, specifically the piperazine derivative subgroup. It is the pharmacologically active enantiomer of cetirizine.

Pharmacodynamics

Levocetirizine Dihydrochloride is a potent and selective antagonist of peripheral histamine H1-receptors. By competitively blocking H1-receptors, it inhibits histamine-mediated effects such as vasodilation, increased vascular permeability, and stimulation of sensory nerve endings, thereby reducing symptoms of allergic rhinitis and urticaria (sneezing, rhinorrhea, pruritus, and wheal-and-flare responses). It has approximately two-fold greater receptor-binding affinity than cetirizine on a molar basis, allowing effective dosing at half the milligram dose of cetirizine.

Pharmacokinetics

• Absorption: Rapidly and extensively absorbed after oral administration; peak plasma concentration reached in about 0.5–1 hour. Food does not significantly affect the extent of absorption but may delay time to peak concentration.
• Distribution: Plasma protein binding is approximately 90%.
• Metabolism: Undergoes minimal hepatic metabolism (less than 14% of the dose), so it is unlikely to be involved in clinically significant hepatic drug-drug interactions.
• Elimination: Predominantly eliminated unchanged in the urine (approximately 85% of the dose) via renal excretion, with a small fraction eliminated in feces. The elimination half-life is approximately 8–9 hours in healthy adults and is prolonged in renal impairment.

Seasonix is administered orally, once daily, preferably in the evening. Tablets should be swallowed whole with a glass of water and may be taken with or without food, although taking with food may slightly delay (without reducing) absorption. Oral solution should be measured using an accurate measuring device (oral syringe or dosing cup), not a household spoon. Do not exceed the recommended dose or frequency.

Seasonix undergoes minimal hepatic metabolism, so clinically significant pharmacokinetic drug interactions are uncommon. However, the following interactions are clinically relevant:

• Alcohol and other CNS depressants (e.g., sedatives, hypnotics, opioids, benzodiazepines): concurrent use may cause additive central nervous system depression and increased sedation/impairment of mental alertness. Alcohol should be avoided during treatment.
• Ritonavir: may increase systemic exposure to cetirizine/levocetirizine; caution advised if co-administered.
• Theophylline: may modestly reduce the clearance of levocetirizine; clinical significance is generally low but caution is reasonable.

No clinically significant interactions have been demonstrated with antipyrine, azithromycin, cimetidine, erythromycin, ketoconazole, or pseudoephedrine.

Most adverse effects of Seasonix are mild and transient. Reported adverse effects include:

Common (adults and adolescents ≥12 years)

• Somnolence/drowsiness (most common, up to ~6%)
• Fatigue
• Dry mouth
• Nasopharyngitis, pharyngitis
• Headache

Common in children

• Somnolence
• Pyrexia (fever)
• Cough, epistaxis (in children 6–12 years)
• Diarrhea, vomiting, otitis media (in younger children)

Rare / post-marketing

• Hypersensitivity reactions including anaphylaxis and angioedema
• Seizures
• Hepatitis, abnormal liver function
• Cardiac arrhythmia
• Psychiatric effects: aggression, agitation, hallucinations, and (rarely) suicidal ideation
• Urinary retention
• Skin rash

Patients should seek prompt medical attention for signs of a severe allergic reaction (swelling of the face/throat, difficulty breathing) or any unusual mood or behavioral changes.

Pregnancy: Data on the use of Seasonix in pregnant women are limited and insufficient to establish a definitive drug-associated risk of major birth defects or miscarriage. Animal reproduction studies have not shown fetal harm at doses far exceeding the maximum recommended human dose. As with most medications during pregnancy, Seasonix should be used only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use during pregnancy.

Lactation: Cetirizine (the parent compound) is excreted into human breast milk, and levocetirizine is expected to be present in breast milk as well. The developmental and health benefits of breastfeeding should be weighed against the mother's clinical need for Seasonix and any potential adverse effects on the breastfed infant, such as sedation. Consult a physician before use while breastfeeding.

Somnolence and CNS effects

Seasonix can cause somnolence and impaired mental alertness, even though it is a low-sedating agent. Patients should be cautioned against driving, operating heavy machinery, or engaging in other hazardous activities requiring full mental alertness until they know how the medication affects them. Concurrent use of alcohol or other CNS depressants should be avoided (see Interactions).

Urinary retention

Antihistamines such as Seasonix have anticholinergic-like effects that may worsen urinary retention, particularly in patients with predisposing factors such as spinal cord lesions or prostatic hyperplasia. Use with caution in such patients and discontinue if urinary retention occurs.

Renal impairment

Because Seasonix is predominantly eliminated by the kidneys, dose reduction is required in patients with renal impairment, and use is contraindicated in end-stage renal disease/hemodialysis (see Dosage and Administration and Contraindications).

Seizure risk

Use with caution in patients with a history of seizures or conditions that lower the seizure threshold, as antihistamines of this class have rarely been associated with seizures.

Elderly patients

Elderly patients may have reduced renal clearance and may be more sensitive to sedative effects; use cautious dosing (see Use in Special Populations).

Overdose of Seasonix may cause somnolence in adults; in children, symptoms may initially include agitation and restlessness followed by drowsiness. There is no specific antidote. Management is symptomatic and supportive; Seasonix is not effectively removed by hemodialysis. In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Use of Seasonix in children follows age-based dosing (see Dosage and Administration). Safety and efficacy have not been established in infants below 6 months of age. Efficacy in children below 12 years is based partly on extrapolation from adult efficacy data combined with pharmacokinetic comparisons.

Geriatric use

Clinical studies did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Because elderly patients are more likely to have decreased renal function, dose selection should be cautious, generally starting at the lower end of the dosing range, with attention to renal function.

Renal impairment

Dose adjustment is required based on creatinine clearance; use is contraindicated in end-stage renal disease/hemodialysis (see Dosage and Administration and Contraindications).

Hepatic impairment

No dose adjustment is required for hepatic impairment alone. In patients with combined hepatic and renal impairment, dose adjustment based on renal function is recommended.

Pregnancy and lactation

See Pregnancy and Lactation section above.

The duration of treatment with Seasonix depends on the indication. For seasonal allergic rhinitis, it is generally used for the duration of allergen exposure/symptom season. For perennial allergic rhinitis and chronic idiopathic urticaria, it may be used for longer-term, continuous daily therapy under medical supervision, with periodic reassessment of continued need. It is not intended for use beyond the period necessary to control symptoms without physician guidance.

Second-generation (low-sedating) H1-antihistamine; piperazine derivative; active enantiomer of cetirizine

Levocetirizine Dihydrochloride acts as a selective antagonist at peripheral histamine H1-receptors. By competitively and reversibly blocking these receptors, it prevents histamine released during allergic reactions from binding and triggering downstream effects such as vasodilation, increased capillary permeability, mucus secretion, and sensory nerve stimulation. This blockade reduces the classic symptoms of allergic rhinitis (sneezing, rhinorrhea, nasal/ocular itching) and urticaria (wheal, flare, and pruritus). It has minimal affinity for other receptor types at therapeutic doses, and limited penetration of the blood-brain barrier accounts for its comparatively low (though not absent) sedative potential relative to first-generation antihistamines.

B

Seasonix is approved for pediatric use with age-based dosing:

• 6 months to 5 years: 1.25 mg once daily (evening), using oral solution — for allergic rhinitis and chronic idiopathic urticaria.
• 6–11 years: 2.5 mg once daily (evening).
• 12 years and above: dosed as adults, 5 mg once daily (evening).

Safety and efficacy have not been established in infants younger than 6 months. Seasonix should not be used in pediatric patients aged 6 months–11 years who have renal impairment, as safe dosing in this subgroup has not been established (see Contraindications). Children 6–11 years should not exceed the recommended 2.5 mg dose, as they have approximately two-fold higher systemic drug exposure compared with adults at the same per-kilogram dose.